Kyverna Therapeutics Inc. (KYTX)
Kyverna Therapeutics Statistics
Share Statistics
Kyverna Therapeutics has 43.21M shares outstanding. The number of shares has increased by 0.23% in one year.
| Shares Outstanding | 43.21M |
| Shares Change (YoY) | 0.23% |
| Shares Change (QoQ) | 0.1% |
| Owned by Institutions (%) | 66.89% |
| Shares Floating | 19.65M |
| Failed to Deliver (FTD) Shares | 994 |
| FTD / Avg. Volume | 0.28% |
Short Selling Information
The latest short interest is 2.87M, so 6.64% of the outstanding shares have been sold short.
| Short Interest | 2.87M |
| Short % of Shares Out | 6.64% |
| Short % of Float | 15.31% |
| Short Ratio (days to cover) | 8.65 |
Valuation Ratios
The PE ratio is -1.12 and the forward PE ratio is -0.98. Kyverna Therapeutics's PEG ratio is 0.
| PE Ratio | -1.12 |
| Forward PE | -0.98 |
| PS Ratio | 0 |
| Forward PS | 0.8 |
| PB Ratio | 0.54 |
| P/FCF Ratio | -1.23 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Kyverna Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.61, with a Debt / Equity ratio of 0.03.
| Current Ratio | 8.61 |
| Quick Ratio | 8.61 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.06 |
| Debt / FCF | -0.07 |
| Interest Coverage | 1004.25 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.14M |
| Employee Count | 112 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -90.28% in the last 52 weeks. The beta is 2.58, so Kyverna Therapeutics's price volatility has been higher than the market average.
| Beta | 2.58 |
| 52-Week Price Change | -90.28% |
| 50-Day Moving Average | 2.77 |
| 200-Day Moving Average | 5.3 |
| Relative Strength Index (RSI) | 38.58 |
| Average Volume (20 Days) | 356K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -142.6M |
| Net Income | -127.48M |
| EBITDA | -142.6M |
| EBIT | -127.62M |
| Earnings Per Share (EPS) | -3.33 |
Balance Sheet
The company has 96.62M in cash and 8.24M in debt, giving a net cash position of 88.38M.
| Cash & Cash Equivalents | 96.62M |
| Total Debt | 8.24M |
| Net Cash | 88.38M |
| Retained Earnings | -263.52M |
| Total Assets | 304.64M |
| Working Capital | 256.85M |
Cash Flow
In the last 12 months, operating cash flow was -114.25M and capital expenditures -2.21M, giving a free cash flow of -116.45M.
| Operating Cash Flow | -114.25M |
| Capital Expenditures | -2.21M |
| Free Cash Flow | -116.45M |
| FCF Per Share | -3.04 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KYTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for KYTX is $20, which is 839% higher than the current price. The consensus rating is "Buy".
| Price Target | $20 |
| Price Target Difference | 839% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -0.23 |
| Piotroski F-Score | 3 |